Literature DB >> 31535416

Epidemiology of sepsis in cancer patients in Victoria, Australia: a population-based study using linked data.

Luc Te Marvelde1,2, Ann Whitfield3, Jennie Shepheard4, Carla Read4, Roger L Milne1,5, Kathryn Whitfield2.   

Abstract

OBJECTIVE: To determine the clinical characteristics, outcomes and longitudinal trends of sepsis occurring in cancer patients.
METHOD: Retrospective study using statewide Victorian Cancer Registry data linked to various administrative datasets.
RESULTS: Among 215,763 incident cancer patients, incidence of sepsis within one year of cancer diagnosis was estimated at 6.4%. The incidence of sepsis was higher in men, younger patients, patients diagnosed with haematological malignancies and those with de novo metastatic disease. Of the 13,316 patients with a first admission with sepsis, 55% had one or more organ failures, 29% required care within an intensive care unit and 13% required mechanical ventilation. Treatments associated with the highest sepsis incidence were stem cell/bone marrow transplant (33%), major surgery (4.4%), chemotherapy (1.1%) and radical radiotherapy (0.6%). The incidence of sepsis with organ failure increased between 2008 and 2015, while 90-day mortality decreased.
CONCLUSIONS: Sepsis in patients with cancer has high mortality and occurs most frequently in the first year after cancer diagnosis. Implications for public health: The number of cancer patients diagnosed with sepsis is expected to increase, causing a substantial burden on patients and the healthcare system.
© 2019 The Authors.

Entities:  

Keywords:  cancer; epidemiology; sepsis

Mesh:

Year:  2019        PMID: 31535416     DOI: 10.1111/1753-6405.12935

Source DB:  PubMed          Journal:  Aust N Z J Public Health        ISSN: 1326-0200            Impact factor:   2.939


  7 in total

1.  Systemic Immune Dysregulation in Early Breast Cancer Is Associated With Decreased Plasma Levels of Both Soluble Co-Inhibitory and Co-Stimulatory Immune Checkpoint Molecules.

Authors:  Bernardo L Rapoport; Helen C Steel; Nomsa Hlatshwayo; Annette J Theron; Pieter W A Meyer; Simon Nayler; Carol-Ann Benn; Teresa Smit; Luyanda L I Kwofie; Liezl Heyman; Ronald Anderson
Journal:  Front Immunol       Date:  2022-05-23       Impact factor: 8.786

2.  Tumor-Specific T Cells Exacerbate Mortality and Immune Dysregulation during Sepsis.

Authors:  Ching-Wen Chen; Kelsey B Bennion; David A Swift; Kristen N Morrow; Wenxiao Zhang; Takehiko Oami; Craig M Coopersmith; Mandy L Ford
Journal:  J Immunol       Date:  2021-04-28       Impact factor: 5.422

3.  Incidence of sepsis and associated mortality within the first year after cancer diagnosis in middle aged adults: A US population based study.

Authors:  Andry Van de Louw; Austin Cohrs; Douglas Leslie
Journal:  PLoS One       Date:  2020-12-28       Impact factor: 3.240

4.  Novel Treatments Targeting the Dysregulated Cell Signaling Pathway during Sepsis.

Authors:  Justin H Franco; Xiaohuan Chen; Zhixing K Pan
Journal:  J Cell Signal       Date:  2021-12

5.  Development and validation of a nomogram for predicting the prognosis in cancer patients with sepsis.

Authors:  Yong Yang; Jun Dong; Yang Li; Renxiong Chen; Xiuyun Tian; Hongzhi Wang; Chunyi Hao
Journal:  Cancer Med       Date:  2022-02-18       Impact factor: 4.711

6.  Comparison of Short- and Long-Term Mortality in Patients with or without Cancer Admitted to the ICU for Septic Shock: A Retrospective Observational Study.

Authors:  Pierrick Le Borgne; Léa Feuillassier; Maleka Schenck; Jean-Etienne Herbrecht; Ralf Janssen-Langenstein; Celestine Simand; Justine Gantzer; Simon Nannini; Luc-Matthieu Fornecker; Karine Alamé; François Lefebvre; Vincent Castelain; Francis Schneider; Raphaël Clere-Jehl
Journal:  Cancers (Basel)       Date:  2022-06-29       Impact factor: 6.575

7.  TIGIT modulates sepsis-induced immune dysregulation in mice with preexisting malignancy.

Authors:  Wenxiao Zhang; Jerome C Anyalebechi; Kimberly M Ramonell; Ching-Wen Chen; Jianfeng Xie; Zhe Liang; Deena B Chihade; Shunsuke Otani; Craig M Coopersmith; Mandy L Ford
Journal:  JCI Insight       Date:  2021-06-08
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.